ARC MIRD Dose Explorer | Effective Half-Life & Absorbed Dose
Appalachian Radiotheranostic Coalition
Interactive dosimetry learning tool
MIRD concepts · made visual

How long activity stays changes how much dose lands.

Move the effective half-life slider and watch the time-activity curve, integrated activity, and absorbed dose change together.

💡
The idea: a longer effective half-life creates a larger area under the activity-versus-time curve. In this simplified MIRD example, that means more time-integrated activity and more absorbed dose.

Activity over time

The shaded area represents time-integrated activity (Ã).

Reference New scenario
At one effective half-life, activity has fallen to 50% of A₀. Time shown in hours
Reference dose
173 mGy
à = 3,462 MBq·h
New scenario dose
346 mGy
à = 6,925 MBq·h
Change from reference
+100%
Dose is higher

Longer retention increases dose

The effective half-life doubled, so time-integrated activity and absorbed dose doubled in this simplified model.

2.00×

Absorbed-dose comparison

Reference
173 mGy
Scenario
346 mGy

The MIRD chain in three steps

Activity curve A(t) decreases over time
Integrate the curve Area = Ã
Apply S D = Ã × S

In a full MIRD calculation, contributions from multiple source regions can be summed for each target region.

Quick challenge

If effective half-life doubles while A₀ and S remain unchanged, what happens to absorbed dose in this model?

Choose an answer to reveal the relationship.
ARC Workshop #2 · Novel Theranostics

Go beyond the slider: see where theranostics is heading next.

Friday, June 26, 2026 · 8:00 AM–5:00 PM · Fralin Biomedical Research Institute at VTC · Roanoke, Virginia · Free registration · 6.25 CE hours

Workshop details & registration
Educational model and limitations. This explorer uses a single monoexponential activity curve, integration to infinity, and a fixed S value. It is intended to demonstrate the mathematical relationship—not to calculate or prescribe patient-specific therapy. Clinical dosimetry may require quantitative serial imaging, multiple source regions, organ/lesion mass adjustment, non-monoexponential kinetics, uncertainty analysis, and radionuclide-specific considerations. References: MIRD Pamphlet No. 21 and IAEA/EANM/SNMMI practical guidance.
Link copied